Scorpius Holdings, Inc. (SCPX)
- Previous Close
0.1052 - Open
0.1061 - Bid 0.1541 x 800
- Ask 0.1620 x 3000
- Day's Range
0.1005 - 0.1180 - 52 Week Range
0.0700 - 0.8900 - Volume
19,552,594 - Avg. Volume
8,874,093 - Market Cap (intraday)
7.369M - Beta (5Y Monthly) 0.03
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date Aug 12, 2024 - Aug 16, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Scorpius Holdings Inc., through its subsidiary Scorpius BioManufacturing, operates as an integrated contract development and manufacturing organization. The company engages in clinical and commercial drug substance manufacturing; and release and stability testing activities. It is also involved in the provision of various process development services, including upstream and downstream development and optimization, and analytical method development solutions, as well as cell line development, testing, and characterization services. The company was formerly known as NightHawk Biosciences, Inc. and changed its name to Scorpius Holdings, Inc. in February 2024. Scorpius Holdings, Inc. was incorporated in 2008 and is based in Morrisville, North Carolina.
www.scorpiusbiologics.comRecent News: SCPX
Performance Overview: SCPX
Trailing total returns as of 5/28/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SCPX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SCPX
Valuation Measures
Market Cap
7.37M
Enterprise Value
19.02M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.39
Price/Book (mrq)
0.22
Enterprise Value/Revenue
2.66
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-33.80%
Return on Equity (ttm)
-82.92%
Revenue (ttm)
6.99M
Net Income Avi to Common (ttm)
-40.15M
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
2.39M
Total Debt/Equity (mrq)
49.63%
Levered Free Cash Flow (ttm)
-18.56M